Urolog. pro Praxi, 2009; 10(3): 168-174

Possibilities in systemic therapy of the prostate cancer

MUDr. Kamil Belej, Ph.D., FEBU2, MUDr. Ondřej Kaplan1,2
1 Urologické oddělení, Klaudiánova nemocnice, Mladá Boleslav
2 Urologické oddělení Ústřední vojenská nemocnice, Praha

Systemic therapy of the prostate cancer comprises an application of the medication influencing primary tumor and also metastases.

This treatment is based on the hormonal therapy combined with prevention and therapy of the bone changes and in some cases chemotherapy.

Current status in this field and possible use of the certain treatment modalities are summarized in the article.

Keywords: prostate cancer, hormonal therapy, bisphosphonates, chemotherapy.

Published: June 1, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Belej K, Kaplan O. Possibilities in systemic therapy of the prostate cancer. Urol. praxi. 2009;10(3):168-174.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Belej K, Kaplan O. Hormonální regulace a možnosti jejího ovlivnění v léčbě karcinomu prostaty. Klin Farmakol Farm 2007; 21(3-4): 114-118.
    2. Widmark A, Klepp O, Solberg A, et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet 2009; 373: 301-308. Go to original source... Go to PubMed...
    3. See WA, Wirth MP, McLeod DG, et al. Bicalutamide (Casodex) 150 mg as immediate therapy either alone or as adjuvant to standard care in patients with localized or locally advanced prostate cancer: first analysis of the Early Prostate Cancer Program. J Urol 2002; 168(2), 429-435. Go to original source... Go to PubMed...
    4. Iversen P, Tyrrell CJ, Kaisary AV, et al. Bicalutamide monotherapy compared with castration in patients with non metastatic locally advanced prostate cancer: 6.3 years of followup. J Urol 2000; 164: 1579-1582. Go to original source... Go to PubMed...
    5. Iversen P, Roder MA. The Early Prostate Cancer program: bicalutamide in nonmetastatic prostate cancer. Expert Rev Anticancer Ther 2008; 8(3): 361-369. Go to original source... Go to PubMed...
    6. McLeod DG, Iversen P, See WA, et al. Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer. BJU Int 2006; 97(2): 247-254. Go to original source... Go to PubMed...
    7. Oefelein MG, Cornum R. Failure to achieve castrate levels of testosterone during luteinizing hormone-releasing hormone agonist therapy: the case for monitoring serum testosterone levels and a treatment decision algorithm. J Urol 2000; 164: 726-729. Go to original source... Go to PubMed...
    8. Mohler J, Prostate Cancer Panel Members. NCCN Clinical Practice Guidelines in Oncology - Prostate Cancer, v. 2. 2009. http://www.nccn.org/professionals/physician_gls/PDF/prostate.pdf. Go to original source... Go to PubMed...
    9. Dušek P, Kawaciuk I, Jarolím L, Teršípová L. Intermitentní androgenní suprese u karcinomu prostaty - desetileté zkušenosti. Vybrané otázky onkologie XI. Praha: Galén, 2007: 77-79.
    10. Seruga B, Tannock IF. Intermittent androgen blockade should be regarded as standard therapy in prostate cancer. Nat Clin Pract Oncol 2008; 5(10): 574-576. Go to original source... Go to PubMed...
    11. Tunn U. The current status of intermittent androgen deprivation (IAD) therapy for prostate cancer: putting IAD under the spotlight. BJU Int 2007; 99(Suppl 1): 19-22. Go to original source... Go to PubMed...
    12. Matoušková M, Hanuš M. Cena hormonální léčby karcinomu prostaty - Farmakoekonomické aspekty indikací léčby. Urolog. pro Praxi 2008; 9(1): 24-27.
    13. Conti PD, Atallah AN, Arruda H, et al. Intermittent versus continuous androgen suppression for prostatic cancer. Cochrane Database Syst Rev 2007; 17(4): CD005009. Go to original source... Go to PubMed...
    14. Sieber PR, Keiller DL, Kahnoski RJ, et al. Bicalutamide 150 mg maintains bone mineral density during monotherapy for localized or locally advanced prostate cancer. J Urol 2004; 171: 2272-2276. Go to original source... Go to PubMed...
    15. Hatano T, Oishi Y, Furuta, A, et al. Incidence of bone fracture in patients receiving luteinizing hormone-releasing hormone agonists for prostate cancer. BJU Int 2000; 86: 449-452. Go to original source... Go to PubMed...
    16. Tuck SP, Francis RM. Testosterone, bone and osteoporosis. Front Horm Res 2009; 37: 123-132. Go to original source... Go to PubMed...
    17. Smith MR. Osteoporosis during androgen deprivation therapy for prostate cancer. Urology, 2002; 60(Suppl 3A): 79-86. Go to original source...
    18. Drake MT, Clarke BL, Khola S. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc 2008; 83(9): 1032-1045. Go to original source... Go to PubMed...
    19. Lein M, Wirth M, Miller K, et al. Markers of bone turnover in men with metastatic prostate cancer treated with zoledronic acid for detection of bone metastases progression. Eur Urol 2007; 52: 1381-1387. Go to original source... Go to PubMed...
    20. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007; 356: 1809-1822. Go to original source... Go to PubMed...
    21. Kolombo I, Kolombová J, Vlásek T. Místo bisfosfonátů při skeletovém postižení v uroonkologii. Urolog. pro Praxi 2006; 5: 228-242.
    22. Kantoff PW, Halabi S, Conaway M, et al. Hydrocortisone with or without mitoxantrone in men with hormonerefractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol 1999; 17: 2506-2513. Go to original source... Go to PubMed...
    23. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502-1512. Go to original source... Go to PubMed...
    24. Berthold DR, Pond GR, Soban F, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 2008; 26: 242-245. Go to original source... Go to PubMed...

    Return to the content


    Urology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.